Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: A role for GPR30/GPER?

Prostate

Volumn 74, Issue 1, 2014, Pages 10-28

  Comeglio, P ^a   Morelli, A ^a   Cellai, I ^a   Vignozzi, L ^a   Sarchielli, E ^a   Filippi, S ^a   Maneschi, E ^a   Corcetto, F ^a   Corno, C ^a   Gacci, M ^a   Vannelli, G B ^a   Maggi, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

bladder; GPR30 GPER; inflammation; metabolic syndrome; prostate; tamoxifen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ANDROGEN RECEPTOR; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CHOLESTEROL; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PROGESTERONE RECEPTOR; RNA 18S; SEX HORMONE; SMALL INTERFERING RNA; TAMOXIFEN; TESTOSTERONE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; FIBROSIS; GENE EXPRESSION; GENE SILENCING; GLUCOSE BLOOD LEVEL; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IC 50; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID DIET; LIVER WEIGHT; LOWER URINARY TRACT SYMPTOM; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE WEIGHT; PROTEIN EXPRESSION; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEMINAL VESICLE; STROMA CELL; TESTIS WEIGHT; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING;

BLADDER; GPR30/GPER; INFLAMMATION; METABOLIC SYNDROME; PROSTATE; TAMOXIFEN;

ANIMALS; CELL LINE; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 8; HUMANS; MALE; METABOLIC SYNDROME X; PAIR BOND; PROSTATE; RABBITS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; URINARY BLADDER;

EID: 84890114923     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22723     Document Type: Article

References (91)

1. Nickel JC,. Prostatic inflammation in benign prostatic hyperplasia-The third component ? Can J Urol 1994; 1: 1-4.
2. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M,. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010; 7: 59-69.
3. Moul S, McVary KT,. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20: 7-12.
4. Donnell RF,. Benign prostate hyperplasia: A review of the year's progress from bench to clinic. Curr Opin Urol 2011; 21: 22-26.
5. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M,. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012; 132: 80-92.
6. Kasturi S, Russell S, McVary KT,. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006; 7: 288-292.
7. Mongiu AK, McVary KT,. Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. Curr Urol Rep 2009; 10: 247-253.
8. Gorbachinsky I, Akpinar H, Assimos DG,. Metabolic syndrome and urologic diseases. Rev Urol 2010; 12: e157-e180.
9. Parsons JK,. Lifestyle factors benign prostatic hyperplasia, and lower urinary tract symptoms. Curr Opin Urol 2011; 21: 1-4.
10. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M,. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000; 163: 1725-1729.
11. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M,. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004; 172: 1390-1393.
12. Tomita K, Mizoue T, Matsumoto T,. Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers. Int J Urol 2009; 16: 493-498.
13. Rohrmann S, Smit E, Giovannucci E, Platz EA,. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2004; 159: 390-397.
14. Seim A, Hoyo C, Ostbye T, Vatten L,. The prevalence and correlates of urinary tract symptoms in Norwegian men: The HUNT study. BJU Int 2005; 96: 88-92.
15. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A,. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008; 179: 1891-1895.
16. Martin SA, Haren MT, Marshall VR, Lange K,., Wittert GA, Members of the Florey Adelaide Male Ageing Study. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community dwelling Australian men. World J Urol 2011; 29: 179-184.
17. Litman HJ, Steers WD, Wei JT, Kupelian V, Link CL, McKinlay JB, Boston Area Community Health Survey Investigators. Relationship of lifestyle and clinical factors to lower urinary tract symptoms: Results from Boston Area Community Health survey. Urology 2007; 70: 916-921.
18. Lotti F, Corona G, Colpi GM, Filimberti E, Degli Innocenti S, Mancini M, Baldi E, Noci I, Forti G, Adorini L, Maggi M,. Elevated body mass index correlates with higher seminal plasma Interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an Andrology Clinic for infertility. J Endocrinol Invest 2011; 34 (10): e336-e342.
19. Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastianelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M,. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013; 73 (8): 789-800.
20. Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M,. Metabolic syndrome and lower urinary tract symptoms: The role of inflammation. Prostate Cancer Prostatic Dis 2013; 16 (1): 101-106.
21. Pradidarcheep W,. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male 2008; 11: 51-55.
22. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M,. Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit. J Endocrinol 2012; 212 (1): 71-84.
23. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, Filippi S, Logiodice F, Carini M, Nesi G, Gacci M, Piccinni MP, Adorini L, Maggi M,. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012; 214 (1): 31-43.
24. Corona G, Mannucci E, Forti G, Maggi M,. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009; 32: 587-598.
25. Zitzmann M,. Testosterone deficiency insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009; 5: 673-681.
26. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M,. Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 2011; 8: 272-283.
27. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M,. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011; 25: 337-353.
28. Traish AM, Miner MM, Morgentaler A, Zitzmann M,. Testosterone deficiency. Am J Med 2011; 124: 578-587.
29. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM,. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008; 168: 1416-1424.
30. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E,. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010; 105: 1554-1559.
31. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, Szalay A, Djavan B, Schmidbauer CP, Söregi S, Madersbacher S,. Endocrine status in elderly men with lower urinary tract symptoms: Correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000; 55: 397-402.
32. Tan AH, Gilling PJ, Kennett KM, Fletcher H, Fraundorfer MR,. Long-term results of high-power holmium laser vaporization (ablation) of the prostate. BJU Int 2003; 92: 707-709.
33. Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ,. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004; 61: 124-131.
34. Miwa Y, Kaneda T, Yokoyama O,. Association between lower urinary tract symptoms and serum levels of sex hormones in men. Urology 2008; 72: 552-555.
35. St Sauver JL, Jacobson DJ, McGree ME, Girman CJ, Klee GG, Lieber MM, Jacobsen SJ,. Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes. Am J Epidemiol 2011; 173: 787-796.
36. Haider A, Gooren LJ, Padungtod P, Saad F,. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalization of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009; 41: 7-13.
37. Saad F, Gooren L, Haider A, Yassin A,. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007; 53: 353-357.
38. Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F,. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: A pilot study. Aging Male 2008; 11: 57-61.
39. Karazindiyanoǧlu S, Çayan S,. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late onset hypogonadism. Aging Male 2008; 11: 146-149.
40. Saad F, Gooren LJ, Haider A, Yassin A,. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008; 29: 102-105.
41. Amano T, Imao T, Takemae K, Iwamoto T, Nakanome M,. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 2010; 13: 242-246.
42. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, Mizokami A, Koh E, Origasa H, Iwamoto T, Namiki M,. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: A randomised controlled study. Aging Male 2011; 14: 53-58.
43. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L,. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011; 30 (3): 292-301.
44. Krajewska M, Banares S, Zhang EE, Huang X, Scadeng M, Jhala US, Feng GS, Krajewski S,. Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase. Am J Pathol 2008; 172: 1312-1324.
45. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M,. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009; 6: 3274-3288.
46. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L, Maggi M,. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011; 8: 57-77.
47. Robinette CL,. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988; 12 (3): 271-286.
48. Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE,. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 2000; 44 (1): 19-25.
49. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, Smit E, Giovannucci E, Platz EA,. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007; 69: 708-713.
50. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC,. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991; 145 (2): 405-409.
51. Meikle AW, Stephenson RA, McWhorter WP, Skolnick MH, Middleton RG,. Effects of age, sex steroids, and family relationships on volumes of prostate zones in men with and without prostate cancer. Prostate 1995; 26 (5): 253-259.
52. Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C, Peeker R, Smith U, Mellström D,. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2009; 12 (2): 160-165.
53. Nicholson TM, Ricke WA,. Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 2011; 82 (4-5): 184-199.
54. Chavalmane AK, Comeglio P, Morelli A, Filippi S, Fibbi B, Vignozzi L, Sarchielli E, Marchetta M, Failli P, Sandner P, Saad F, Gacci M, Vannelli GB, Maggi M,. Sex steroid receptors in male human bladder: Expression and biological function. J Sex Med 2010; 7 (8): 2698-2713.
55. Couse JF, Korach KS,. Estrogen receptor null mice: What have we learned and where will they lead us ? Endocr Rev 1999; 20: 358-417.
56. Hess RA,. Estrogen in the adult male reproductive tract: A review. Reprod Biol Endocrinol 2003; 1: 52.
57. Li X, Rahman N,. Impact of androgen/estrogen ratio: Lessons learned from the aromatase over-expression mice. Gen Comp Endocrinol 2008; 159: 1-19.
58. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ,. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008; 70: 165-190.
59. Vignozzi L, Filippi S, Morelli A, Comeglio P, Cellai I, Sarchielli E, Maneschi E, Mancina R, Gacci M, Vannelli GB, Maggi M,. Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors. J Sex Med 2012; 9 (12): 3028-3040.
60. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI,. Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002; 16: 70-84.
61. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG,. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci 2005; 25: 5066-5078.
62. Thomas P, Pang Y, Filardo EJ, Dong J,. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146 (2): 624-632.
63. Maneschi E, Morelli A, Filippi S, Cellai I, Comeglio P, Mazzanti B, Mello T, Calcagno A, Sarchielli E, Vignozzi L, Saad F, Vettor R, Vannelli GB, Maggi M,. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol 2012; 215 (3): 347-362.
64. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER,. A transmembrane intracellular estrogen receptor mediates rapid cell signalling. Science 2005; 307: 1625-1630.
65. Crescioli C, Maggi M, Vannelli GB, Luconi M, Salerno R, Barni T, Gulisano M, Forti G, Serio M,. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 2000; 85: 2576-2583.
66. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, Maggi M,. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: An experimental study in the rabbit. Prostate 2013; 73 (4): 428-441.
67. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M,. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-1029.
68. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M,. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009; 6: 1594-1608.
69. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozzi L, Fibbi B, Silvestrini E, Sandner P, Gacci M, Carini M, Vannelli GB, Maggi M,. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010; 7: 107-120.
70. De Lean A, Munson PJ, Rodbard D,. Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978; 235: E97-E102.
71. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P,. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990; 9 (5): 1603-1614.
72. Gronemeyer H, Meyer ME, Bocquel MT, Kastner P, Turcotte B, Chambon P,. Progestin receptors: Isoforms and antihormone action. J Steroid Biochem Mol Biol 1991; 40 (1-3): 271-278.
73. Ing NH, Tornesi MB,. Estradiol up-regulates estrogen receptor and progesterone receptor gene expression in specific ovine uterine cells. Biol Reprod 1997; 56: 1205-1215.
74. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L,. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kB pathways. Prostate 2009; 69: 480-493.
75. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M,. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475-488.
76. Nilsson S, Gustafsson JA,. Estrogen receptors: Therapies targeted to receptor subtypes. Clin Pharmacol Ther 2011; 89 (1): 44-55.
77. Pettersson K, Delaunay F, Gustafsson JA,. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000; 19: 4970-4978.
78. Ho CK, Nanda J, Chapman KE, Habib FK,. Oestrogen and benign prostatic hyperplasia: Effects on stromal cell proliferation and local formation from androgen. J Endocrinol 2008; 197 (3): 483-491.
79. Lau KM, LaSpina M, Long J, Ho SM,. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000; 60 (12): 3175-3182.
80. Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A, Sinisi AA,. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 2001; 86 (5): 2051-2055.
81. Royuela M, de Miguel MP, Bethencourt FR, Sánchez-Chapado M, Fraile B, Arenas MI, Paniagua R,. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001; 168 (3): 447-454.
82. Tsurusaki T, Aoki D, Kanetake H, Inoue S, Muramatsu M, Hishikawa Y, Koji T,. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 2003; 88 (3): 1333-1340.
83. Fixemer T, Remberger K, Bonkhoff H,. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003; 54 (2): 79-87.
84. Yamashita S,. Localization of estrogen and androgen receptors in male reproductive tissues of mice and rats. Anat Rec A Discov Mol Cell Evol Biol 2004; 279 (2): 768-778.
85. De Friend DJ, Anderson E, Bell J, Wilks DP, West CM, Mansel RE, Howell A,. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70: 204-211.
86. Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdicchio MA, Napolitano M, Nola E, Moncharmont B, Medici N, Nigro V, Armetta I, Abbondanza C, Puca GA,. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res 2000; 60: 2594-2597.
87. Chan CR, Hsu JT, Chang IT, Young YC, Lin CM, Ying C,. The effects of glutamate can be attenuated by estradiol via estrogen receptor dependent pathway in rat adrenal pheochromocytoma cells. Endocrine 2007; 31: 44-51.
88. Kunath F, Keck B, Antes G, Wullich B, Meerpohl JJ,. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: A systematic review. BMC Med 2012; 10: 96.
89. Saltzstein D, Sieber P, Morris T, Gallo J,. Prevention and management of bicalutamide-induced gynecomastia and breast pain: Randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005; 8 (1): 75-83.
90. Naslund MJ, Strandberg JD, Coffey DS,. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988; 140 (5): 1049-1053.
91. Stoker TE, Robinette CL, Cooper RL,. Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: Evaluation of inflammation in the ventral and lateral lobes. Reprod Toxicol 1999; 13 (6): 463-472.